Four States Selected for NASHP’s Public Health Modernization Learning Collaborative
/in Policy, Population Health Arkansas, Indiana, Michigan, Rhode Island Blogs, Featured News Home /by Shaza Stevenson, Ella Roth and Katie GreeneWhile COVID-19 has revealed longstanding gaps and challenges across public health systems, the pandemic has also catalyzed new collaborations and broke down traditional silos between public health and the broader healthcare system. As state leaders look to incorporate lessons learned from the pandemic and modernize public health systems, states are increasingly developing approaches to collaborate across sectors, meaningfully engage communities, and align efforts across health system partners.
The National Academy for State Health Policy (NASHP), with support from the Commonwealth Fund, will convene cross-agency state teams for a one-year learning collaborative beginning October 2022. NASHP will support participating states in developing action plans for advancing key goals related to leveraging and integrating data systems, effectively engaging multi-sector partners to advance public health goals, and expanding the reach and impact of place-based strategies to address community-identified needs. States selected to participate in this learning collaborative are:
- Arkansas
- Indiana
- Michigan
- Rhode Island
The learning collaborative will support state leaders in developing a modernized public health system that is robust, interconnected, and capable of both promoting the health of all communities and addressing the challenges ahead. During winter 2022, NASHP will also release a resource toolkit containing key priorities and strategies for fostering public health and healthcare system partnerships on key public health goals. For more information on NASHP’s Public Health Modernization project and the Public Health Modernization State Leaders workgroup, visit our project announcement.
Acknowledgement: This learning collaborative is supported by the Commonwealth Fund.
Developing Meaningful and Effective Partnerships between State Leaders and Community Health Worker Associations
/in Community Health Workers, Policy North Carolina, Rhode Island Blogs, Featured News Home Health Equity, Social Determinants of Health /by Elinor Higgins and Megan D’AlessandroHow States Use Cost-Growth Benchmark Programs to Contain Health Care Costs
/in Health System Costs Connecticut, Delaware, Massachusetts, Rhode Island, Washington Charts, Featured News Home Consumer Affordability, Health System Costs, Hospital/Health System Oversight, Making the Case for Action, Total Cost of Care Benchmark /by Deborah Fournier and Adney RakotoniainaState Cross-Agency Collaboration during the COVID-19 Pandemic Response
/in COVID-19 Relief and Recovery Resource Center, COVID-19 State Action Center Illinois, Indiana, Rhode Island Featured News Home, Reports COVID-19 /by Elinor Higgins and Rebecca CooperRhode Island’s Accountable Entities Emphasize Children’s Health and Social Needs
/in Policy Rhode Island Blogs, Featured News Home Chronic and Complex Populations, Eligibility and Enrollment, Eligibility and Enrollment, Health Coverage and Access, Health Equity, Housing and Health, Integrated Care for Children, Maternal, Child, and Adolescent Health, Physical and Behavioral Health Integration, Population Health, Social Determinants of Health /by Elinor HigginsIn the midst of the pandemic, many states are continuing to advance their health system transformation efforts. Rhode Island’s Medicaid Accountable Entities (AE) Program, for example, is shifting to a pay-for-performance model for several screening measures. Under this model, there is an additional financial incentive to screen children and their families for health and social needs, which have taken on new importance due to the added stressors of COVID-19.
Rhode Island’s AE program, now entering its fourth year, makes provider organizations (AEs) accountable for health outcomes of their members as well as the total cost of care of their populations. Using contractual levers in the agreements between AEs and managed care organizations (MCOs), the state requires AEs to integrate strategies to address social needs and social determinants of health (SDOH). The strategies must include assessment of social needs, referral to community resources, and utilizing community partnerships and engagement to address the identified needs.
Read NASHP’s 2018 profile of Rhode Island’s Accountable Entities Program here.
The state developed SDOH screening requirements for the AEs. Screening tools must be approved by the Rhode Island Executive Office of Health and Human Services (EOHHS), and they must include information on the following domains: housing insecurity, food insecurity, transportation, interpersonal violence, and utility assistance.
Screening for a child’s needs can offer insights about what kinds of services, referrals, or wrap-around care are needed to ensure healthy development. Because the ongoing pandemic has required children and families to stay home and spend additional time together, a safe and supportive home environment is especially crucial for children’s health and well-being. The SDOH screening domains that are required by EOHHS overlap with adverse childhood experiences (ACEs), such as poverty, food and/or housing insecurity, neglect, and mental illness — all of which contribute to poor health outcomes for children.
Rhode Island’s AE program takes into account the benefit of a two-generation (2Gen) approach to these issues. Under a 2Gen framework, services are provided to both children and the adults in their lives simultaneously to help families live healthy and productive lives. When screening children under age 12, Rhode Island’s SDOH screening measure can be applied to an entire household instead of to only the individual child. This can provide a better understanding of how to target interventions for the whole family going forward.
This year, a key change is happening within the AE program that may increase the number of children and families served by the program. The state is shifting to pay-for-performance (P4P) for the SDOH screening requirement. Beginning in Project Year 4 (PY4), there is a financial incentive for the AEs to increase their SDOH screening rates among their attributed populations. AEs needed time to develop their screening tools and build capacity around screening for SDOH before shifting the AE incentive metric to P4P. Other measures, including documented developmental screening for children younger than age 3, will also transition to P4P in PY4.
Though the SDOH screening requirements are specific to Medicaid AEs in Rhode Island, state officials expect the screening requirements to have a ripple effect. In primary care settings, for example, if a provider is administering the SDOH to AE-attributed patients, officials expect they are likely integrating the screening into their workflows and administering it to all of their patients. This has proven to be the case with other well-child practices. For example, the AE Coastal Medical, has implemented universal screenings across all of its practices to assess and identify needs around depression, anxiety, and SDOH.
Screening is only the first step in improving health-related social needs for children and families. One of the goals of the AE program is to use screening results and the improved understanding of its members’ circumstances to improve their overall health. Rhode Island is leveraging its Quality Report System (QRS), a tool for data collection, to calculate performance on the quality measure. This tool enables providers to drill down to the patient level to identify patients still in need of screening.
An upcoming strategy to help AEs coordinate better with community partners is the procurement of a community referral system that would help connect individuals to necessary resources. Such a referral network could be linked with the QRS in the future, making data collection, analysis, and referral a centralized process. Ultimately, this initiative may drive a broader conversation about how the state collects screening data across both public and private payers, and how this data can be used to improve the health outcomes of Rhode Island residents.
Nine States Advance Prescription Drug Affordability Board Legislation
/in Prescription Drug Pricing Arizona, Colorado, Minnesota, New Jersey, New Mexico, Oregon, Rhode Island, Virginia, Wisconsin Blogs, Featured News Home Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer Reck and Trish RileyMore than 200 bills to lower drug prices have been filed across states during this session and nine states are proposing prescription drug affordability board (PDAB) legislation.
PDABs are somewhat analogous to public utility commissions. They investigate high-priced drugs and, when necessary, set more affordable rates for certain drugs for purchasers within a state. Establishing health care provider and hospital payment rates is a common approach states use to ensure services are affordable. State PDABs extend this strategy to a subset of very costly prescription drugs, while avoiding unlawful patent preemption because they establish drug payment rates – not prices. The National Academy for State Health Policy (NASHP) developed model legislation for this approach in 2017 and in 2019 Maryland became the first state in the nation to enact PDAB legislation.
This chart highlights nine states’ bills to create prescription drug affordability boards, including their implementation timelines, funding sources, enforcement, and purchasers impacted.
Nine states (AZ, CO, MN, NJ, NM, OR, RI, VA, and WI) are currently advancing PDAB bills in their legislatures. While a number of these bills are similar to Maryland’s approach that phases in upper payment limits by initially limiting them to public purchasers before potentially expanding them to include private purchasers, the majority of the currently proposed bills map more closely to NASHP’s original model legislation, which implements payment limits across all payers (public and private) in a state in a more expedited fashion.
The bills are generally similar in two approaches:
- They use similar price thresholds to identify a drug for investigation by their PDABs, and
- They apply the same factors when setting an upper payment limit for drugs found to be otherwise unaffordable – such as weighing the cost of administering the drug and delivering the drug to consumers.
Minnesota’s bill, however, includes unique language that empowers its PDAB to consider both the “the range of prices at which [a] drug is sold in the United States and the range at which pharmacies are reimbursed [for it] in Canada.” This language creates a bridge between the PDAB model and a newer approach in a recently released NASHP model law that creates payment rates for certain high-priced drugs based on Canadian pricing. This approach, reflected in NASHP’s Act to Reduce Prescription Drug Costs Using International Pricing, offers states a more streamlined approach than establishing a PDAB, which requires the complex task of determining the appropriate value of a drug in order to set an affordable payment rate. Five states (HI, ME, OK, ND, and RI) are currently considering international reference rate bills that use (or “reference”) Canadian prices to set more affordable rates.
As states consider PDABs and international reference rate approaches to achieve the goal of setting more affordable payment rates for drugs, there are several key factors to consider.
- While international reference rates look to Canada’s drug prices when establishing appropriate payment rates, PDABs keep the task of identifying affordable rates within a state.
- While PDABs may be conceptually preferable for this reason, the time and resources required to implement this approach may not make PDABs feasible for all states. For those states, using Canadian prices to set rates may be the most viable option.
Minnesota’s bill, however, points to a third option, a hybrid approach in which a PDAB would consider Canadian pricing as part of its process.
Explore this chart to compare the different state approaches and implementation timelines of the nine PDAB bills proposed as of March 9, 2021.
Federal and State Special Enrollment Periods Increase Access to Insurance Coverage
/in Policy California, Colorado, Connecticut, District Of Columbia, Idaho, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Washington Blogs, Featured News Home Eligibility and Enrollment, Health Coverage and Access, State Insurance Marketplaces /by Christina CousartFive Trailblazing States Consider Legislation to Capture Big Rx Savings Using Canadian Reference Rates
/in Prescription Drug Pricing Hawaii, Maine, North Dakota, Oklahoma, Rhode Island Blogs, Featured News Home Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer Reck and Trish RileyBurdened by high US drug prices that average 218 percent more than in Canada, innovative states across the country are exploring a range of approaches to give their residents the same access to affordable drugs Canadians have. To date, six leading states have passed laws that enable them to import drugs from Canada pending federal approval of their programs. Now, a second set of trailblazing states are exploring an alternative approach that does not require federal approval – importing Canadian drug prices.
Lawmakers in five states (HI, ME, OK, ND, and RI) have introduced or pre-filed bills based on the National Academy for State Health Policy’s (NASHP) model legislation to establish international reference rates using Canadian pricing.
Establishing payment rates for hospitals’ and providers’ services is common to ensure access to affordable care. The NASHP model extends that practice to prescription drugs, giving states a powerful tool to limit what payers within a state will pay, without running afoul of patent law by setting prices.
What is international reference rate legislation?
International reference rate legislation authorizes a state’s department of insurance to establish international reference rates for the costliest drugs in that state. The department determines the reference rates based on those drugs’ prices in Canada’s four largest provinces. The lowest price would become the legal upper payment limit for those drugs for participating purchasers in the state.
A savings analysis NASHP facilitated for one state considering this legislative approach, showed annual savings of more than $32 million for just 35 drugs purchased by state employees alone. States are proposing setting reference rates for up to 250 drugs for all commercial payers, including Medicare advantage plans (Medicaid and traditional Medicare would be excluded), so total savings would far exceed that initial estimate.
Under the model legislation, any savings generated must be shared with consumers through mechanisms left to the discretion of a state. Options may vary by payer, ranging from reducing premiums for commercial payers, maintaining or expanding access to Medicaid services, and avoiding tax increases for public payers.
Oklahoma state Sen. Greg McCortney identified the potential for savings as key. “I do not believe that we can fix our broken health care system until we address the cost of care,” he said. “This bill, once fully implemented, should reduce insurance premiums for every person in the state by hundreds of dollars each year.”
The model law’s implementation process is designed to be easy for a state to administer and does not require costly infrastructure at a time when states are burdened by the pandemic and budgetary restraints. As a proxy for all commercial payers, the bill uses a state’s employee health plan to identify the costliest 250 drugs, determined by drug price times utilization.
- The state employee health plan shares the list of 250 drugs with the Department of Insurance.
- The department then establishes references rates by comparing publicly available data on drug prices in Canada’s four most populous provinces. The lowest price becomes the reference rate for payers within the state.
- No commercial payer could pay more than the reference price established by the state’s department of insurance, and a manufacturer that withdrew a drug or refused to negotiate in good faith would be subject to significant penalties.
As states move forward in their legislative sessions, states are adapting NASHP’s reference rate model and making it their own. They’re exploring variations in the roles their agencies would play, as well as possibly limiting the number of referenced drugs to a smaller group that would have maximum impact.
Insurance Rate Review as a Hospital Cost Containment Tool: Rhode Island’s Experience
/in Policy Rhode Island Blogs, Featured News Home Consumer Affordability, Health System Costs, Hospital/Health System Oversight, Making the Case for Action /by Johanna ButlerFor more than a decade, Rhode Island has used a unique insurance rate review approach to keep hospital costs from rising any more than inflation plus 1 percent. As states confront COVID-19 and its accompanying budget crisis, Rhode Island’s approach that allows regulators to oversee hospital costs and requires insurers to invest in the state’s health priorities offers a new model for curbing health care costs.
From Medicare reference-based pricing to cost-growth benchmarks, states are exploring a number of innovative approaches to stabilize health care costs. Hospital costs are a particularly significant driver of insurance premiums rates. As health care consolidation increases, costs rise and insurers may be less likely to exert negotiating power to lower those costs.
As states renew their focus on health care costs, Rhode Island’s affordability standards, which require the inflation plus 1 percent cap in insurers’ negotiated prices with hospitals in order to have their premium rates approved, offers an avenue for health care cost controls. While the degree of regulatory oversight over insurance markets varies across the country, many states may be able to replicate Rhode Island’s approach.
Background on Insurance Rate Review
The insurance rate review regulatory tool gives state insurance departments the authority to examine proposed premium increases charged by health insurance companies that offer plans in a state. Rate review is used both to assure the financial viability of insurers and to ensure that companies have a legitimate reason to raise costs.
While rate review was ongoing on the state-level before the Affordable Care Act (ACA) was enacted, the ACA created a floor for review of “unreasonable” increases or a 10 percent increase in the individual or small-group market. The federal government defers to state review of premium rate changes unless a state doesn’t have an “effective” program, defined by the Centers for Medicaid & Medicare Services’ Center for Consumer Information and Insurance Oversight. Currently only three states (Oklahoma, Texas, and Wyoming) defer to the federal government for rate review. The ACA also added in the medical loss ratio (MLR) requirement, which limits the amount of premium dollars that insurers can spend on administration, marketing, and profits. The ACA requires most individual and small-group market insurers to spend 80 percent of premium income on health care claims and limits other expenses to the remaining 20 percent of premium income.
Rhode Island’s affordability standards successfully curbed hospital costs by:
• Limiting contracted hospital prices from rising any more than inflation plus 1 percent;
• Reducing quarterly per enrollee spending by an average $55 from 2010 to 2016; and
• Lowering patient-cost sharing while not impacting quality metrics or utilization.
The scope of rate review varies across states – some states only have authority over individual and small-group markets while others also have authority over the fully insured, large-group markets as well. Some states have “prior approval” authority, which allows them to reject, approve, or reduce proposed premium rates, while others have “file-and-use” oversight, which gives officials the authority to review, but not reject proposed increases. Whether states have prior approval or file-and-use authority can also vary based on the market – states typically have less oversight over the fully insured, large-group market than the individual and small-group market.
In 2015, Health Affairs reported that adjusted premiums in the individual market were lower in states that had “prior approval” authority along with MLR requirements from 2010 to 2013. While more stringent rate review is shown to keep premiums lower, some states have expanded the scope of their rate review processes to tackle issues of accessibility and affordability. Since 2010, Rhode Island has been using its unique regulatory structure with the Office of the Health Insurance Commissioner (OHIC) to better control rising hospital costs through insurance rate review.
Rate Review as a Cost Containment Tool
In 2004, Rhode Island enacted a law that split the Office of the Health Insurance Commissioner (OHIC) from the rest of its insurance department in order to better understand and oversee the relationship between insurers and providers. In Rhode Island, the health insurance commissioner has oversight over the individual market, the small-group market, and fully insured, large-group markets. Although the ACA required the OHIC to complete a more comprehensive review of consumer protections in the individual and small-group markets, the OHIC has the authority to review and approve rates for all three markets – including for fully insured, large-group plans.
The legislature also charged the newly created health insurance commissioner with promoting greater accessibility, quality, and affordability in the health insurance market – a unique charge compared to other states – that ultimately led insurance regulators to oversee negotiated rates between insurers and hospitals. The OHIC’s work to oversee hospital costs largely relies on a “public interest” criterion in the state’s insurance statutes. The rate review statute requires proposed rates to be, “consistent with the proper conduct of its business and with the interest of the public,” and the public has an interest in affordability. The 2004 statute also created the Health Insurance Advisory Council, which was responsible for making recommendations on a number of issues, including requiring that the market for small businesses be affordable and fair.
The council led efforts to better understand health care cost drivers in Rhode Island and found that hospitals were a main “pain point” for affordability. Insurers argued they did not have the leverage to negotiate lower rates in contracts with providers. In 2009, the council reviewed the state’s options to address these cost drivers and eventually developed the Affordability Standards and Priorities for Rhode Island Commercial Health Insurers, which emphasized the need for reduced insurance costs, and by extension, reduced hospital costs. In 2010, the insurance commissioner documented significant variances between the rates of payment for inpatient costs across health systems in Rhode Island, prompting additional questions about the contracted rates between insurers and providers. This finding, combined with a lack of insurer-motivated payment reforms, spurred the commissioner to adopt a set of four “affordability standards” for insurance rate review.
Rhode Island’s Affordability Standards
With the adoption of the affordability standards, the commissioner directed insurers to comply with four new criteria in order to have their premium rates approved:
- Expanding and improving primary care infrastructure;
- Spreading the adoption of the patient-centered medical home model;
- Supporting CurrentCare, the state’s health information exchange; and
- Working toward comprehensive payment reform across the delivery system.
The primary care criteria required insurers to increase their share of medical spending on primary care by 1 percent from 2010 to 2014, while not increasing consumer premiums. The additional investments also couldn’t lead to increased overall medical expenses – and instead were intended to reflect a shift to new payment strategies. Beyond primary care, the standards required insurers to provide financial support for the Rhode Island Chronic Care Sustainability Initiative, the all-payer, patient-centered medical home pilot project, and CurrentCare, the state’s health information exchange
As far as cost containment, the most striking change to Rhode Island’s rate review process was the implementation of the fourth standard – comprehensive payment reform. In order to set measurable goals to hold insurers accountable for this, the commissioner put six conditions into place that insurers had to adopt in their hospital contracts. The conditions included:
-
- Paying for inpatient and outpatient services using “units of service” that encourage efficient resource use.
- Limiting the average annual effective rates of price increase for both inpatient and outpatient services to a weighted amount equal to or less than Centers for Medicare & Medicaid Services’ National Prospective Payment System Hospital Input Price Index (“IPPS”) plus 1 percent for all contractual years.
- Giving hospitals an opportunity to increase total annual revenue based on meeting mutually agreed upon quality goals.
- Including contract terms to meet agreed upon obligations for administrative simplification.
- Including contract terms that promote and measure improved care coordination.
- Including transparency for these six terms in contracts.
The #2 condition, requiring insurers to limit the average price increases for hospital services, was groundbreaking in its impact on the contractually agreed-upon prices paid by insurers to providers. In addition to tagging rate increases to IPPS, the affordability standards also required that at least 50 percent of the annual hospital rate increases be earned through the agreed-upon quality measures. These hospital contracting provisions were an early and still innovative approach to regulating hospital costs.
Impact of Affordability Standards
A 2019 Health Affairs review found that implementation of Rhode Island’s affordability standards led to a net reduction in per enrollee spending by a mean of $55 from 2010 to 2016. The study showed that outpatient and inpatient utilization did not significantly change, but spending per encounter decreased in Rhode Island compared to a control group. Quarterly fee-for-service spending actually decreased by $76 per enrollee, but the requirement to increase non-fee-for-service primary care spending raised per enrollee spending by $21, netting out to a quarterly savings per enrollee of $55. In addition, patient cost sharing was lower in Rhode Island after the affordability standards were implemented compared to a control group.
Quality metrics did not change with implementation of the standards. In fact, interviews conducted for a 2013 review of the standards found that the “at-least-50-percent” provision for hospital contracting caused a “culture shift” among hospitals by focusing their attention to meeting quality measures.
The one challenge in understanding the impacts of Rhode Island’s affordability standards is that it is impossible to totally untie the provisions around hospital contracting from the primary care investments, making it somewhat difficult to know how a state might fare if it only enacted standards around payment reform without the primary care investment.
Since implementation in 2010, Rhode Island has updated its affordability standards over time to align with other goals, such as further promoting the patient-centered medical home model and alternative payment methods that emphasize value rather than volume. The most recent affordability standards, adopted in 2016, require insurers to spend at least 10.7 percent of their annual medical spend on primary care. Among other requirements, the standards also maintain the hospital contracting provisions. The standards require insurers to limit hospital rate increases so that the average rate increase is no greater than the Urban Consumer Price Index (CPI) (less food and energy) percentage increase plus 1 percent.
Future of Rate Review as a Cost Containment Tool
Rate review is a promising tool for cost containment. As evidence shows it can keep premiums low but can also be used to impact payer-provider negotiations as in Rhode Island. Placing responsibility for hospital cost containment alongside insurance rate review not only allows for coordinated reform across insurers, but also gives an insurance department, like OHIC, insight into where unintended consequences might occur or other costs might pop up as the state works to control other health care cost drivers.
States have begun to mirror Rhode Island’s affordability standards in their insurance rate review process to advance health policy goals. In 2019, Colorado enacted HB 19-1233, which established a Primary Care Reform Payment Collaborative that, among other things, was tasked with creating an affordability standard to require additional investment by insurers in primary care.
The collaborative recommended that commercial payers be required to increase the percentage of total medical expenditures (excluding pharmacy) spent on primary care by at least one percentage point annually through 2022. The collaborative said the Insurance Commissioner will have to address the risk of costs being passed on to consumers when the affordability standards are promulgated. This standard is similar to Rhode Island’s work to invest in its primary care infrastructure. Importantly, the Colorado collaborative noted in its recommendations that the Insurance Commissioner must include this new affordability standard alongside an effort to reduce overall health care spending. Otherwise, health care costs could rise in the state.
Similarly, Delaware enacted SB 116 in 2019 to create an Office of Value-Based Health Care Delivery within its Department of Insurance. The office’s goal is to reduce health care costs by providing high quality, cost-efficient health insurance products with stable, predictable, and affordable rates. To achieve this mandate, the new Delaware office has been working alongside the Delaware Primary Care Reform Collaborative to develop affordability standards and targets for primary care spending for carriers. In November 2020, the office presented draft affordability standards that would set targets for primary care investment, unit price growth for non-professional services, and the adoption of alternative payment models. Modeling Rhode Island’s work, the targets for primary care investment and capping unit price growth would be enforced through insurance rate review. The draft standards recommend using a phased approach to cap unit price growth beginning in 2022 and would decrease over time, eventually reaching Rhode Island’s cap of CPI plus one percent by 2025. According to a timeline in its November presentation, the office plans to publish the draft standards and accept public comments in February 2021.
With the implementation of Rhode Island’s affordability standards, the state was able to successfully cap growth in hospital costs and thereby constrain premium growth. Rhode Island’s use of rate review to control hospital costs can be a model for other states interested in curbing health care costs. The National Academy for State Health Policy will continue to track state efforts to implement affordability standards and will convene states interested in exploring this policy.
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 























































































































































